文献速递银屑病与炎症性皮肤病

中重度银屑病患者生物制剂转换:法国PSOBIOTEQ队列研究结果

Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-07-22

基于法国PSOBIOTEQ多中心队列2153例接受首个生物制剂的中重度银屑病成人患者,描述生物制剂间转换模式及随时间的变化。首个生物制剂3年累积转换发生率为34%,转换主因为疗效丧失(72%),其次为不良事件(11%)。2016年前后转换去向由乌司奴单抗转向IL-17抑制剂。

要点

  • 首个生物制剂3年累积转换发生率为34%,阿达木单抗和乌司奴单抗为一线与二线最常用药物。
  • 转换主因为疗效丧失(72%),其次为不良事件(11%)。
  • 2016年前转换多去向乌司奴单抗,2016年及以后多去向IL-17抑制剂。

核心结论

  • 本研究描述了生物制剂治疗的转换模式,并显示因新生物制剂(主要为IL-17抑制剂)的可及,转换模式随时间发生变化。

研究设计与样本

  • Psobioteq多中心队列纳入接受全身治疗的中重度银屑病成人患者中接受首个生物制剂者,共2153例。
  • 采用时间图、桑基图和旭日图描述生物制剂间转换,用竞争风险生存分析评估首次转换累积发生率及转换原因。
  • 用多因素logistic回归分析从TNF-α抑制剂转换患者中转换类型(同类内 vs 类间)的相关因素。

主要发现

  • 首个生物制剂3年累积转换发生率为34%。
  • 阿达木单抗和乌司奴单抗为一线和二线治疗中最常处方的生物制剂。
  • 转换主因为疗效丧失(72%),其次为不良事件(11%)。
  • 2016年前接受TNF-α抑制剂者多转换为乌司奴单抗,2016年及以后转换者多转换为IL-17抑制剂。
  • 与2018年以来转换者相比,2016年前从一线TNF-α抑制剂转换者更可能转换为另一种TNF-α抑制剂。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biologics are the cornerstone of treatment of patients with moderate-to-severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time. OBJECTIVES: The main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents. METHODS: We included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate-to-severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra-class - i.e. within the same therapeutic class - vs. inter-class) in patients switching from a TNF-alpha inhibitor using multivariate logistic regression. RESULTS: A total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3 years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF-alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL-17 inhibitor. Patients switching from a first-line TNF-alpha inhibitor before 2016 were more likely to switch to another TNF-alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF-alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab. CONCLUSION: This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL-17 inhibitors.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Curmin R, Guillo S, De Rycke Y, et al. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2022. PMID: 35793473. doi:10.1111/jdv.18409

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。